BioSpace News Archive

Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced the U.S. Food and Drug Administration (FDA) granted a Rare Pediatric Disease (RPD) designation to the Company’s lead compound, INV-101, for the treatment of Prader-Willi syndrome (PWS).

CURE Pharmaceutical Holding Corp (“CURE” or the “Company”) (OTC: CURR), a technology-focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced today that the Company’s Chief Executive Officer Rob Davidson will be presenting at the H.C. Wainwright BioConnect 2021 Virtual Conference being held January 11-14. The presentation can be viewed

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today provided a corporate update, product pipeline timing and anticipated milestones for 2021. Financial Update and Key Launch Metrics: Preliminary Unaudited Full Year 2020 RHA® Collection Revenue of Between $12.5 Million and $13.0 Million. The company expects its first full quar

Abiomed (NASDAQ: ABMD) announces it has surpassed more than 1,000 patents worldwide, with more than 850 additional patents pending. Abiomed’s robust intellectual property portfolio protects its current and future pump and catheter designs, along with other product components such as motors, cannulas, sensors, software, and access devices. The portfolio also protects manufacturing processes and future artificial intellige

AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company will be participating in this year’s Biotech Showcase Digital 2021 conference. James Sapirstein, President & CEO of AzurRx BioPharma, and the Company’s senior management team will be participating in virtual one-on-one meet

Konica Minolta Healthcare Americas Inc. and strategic partner AGIMED, a leading healthcare distributor in Argentina, jointly announce the implementation of Konica Minolta imaging management solutions across the primary public health hospital system in Córdoba, Argentina’s second largest region.

Tauriga Sciences, Inc., a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums as well as two ongoing Biotechnologies initiatives, announced that its Board of Directors has unanimously voted to terminate its Equity Line of Credit due to substantially improved fundamentals, macro-business outlook, and corporate balance sheet.

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to provide an overview of the Company’s primary plans for the upcoming calendar year.

Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the fourth quarter and fiscal year ended December 31, 2020 after the market closes on March 3, 2021 at approximately 4:00 p.m. Eastern Time

The Board of Alterity Therapeutics is pleased to announce the appointment of Dr David Stamler to the role of Chief Executive Office effective immediately.